Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial of N-115 (Non-Steroidal Nasal Spray) for the treatment of COVID-19

Trial Profile

A clinical trial of N-115 (Non-Steroidal Nasal Spray) for the treatment of COVID-19

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Mar 2020

At a glance

  • Drugs Sodium pyruvate (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Mar 2020 New trial record
    • 17 Mar 2020 According to an EmphyCorp media release, N115 Non-Steroidal Nasal Spray is currently being tested in clinical trials as a potential treatment for patients infected with the Coronavirus.

Trial Overview

Purpose

This trial will assess N-115 (Non-Steroidal Nasal Spray) for the treatment of COVID-19.

Diseases Treated

Indication Qualifiers Patient Segments
COVID 2019 infections prevention -

Subjects

  • Subject Type patients
  • Sex not stated

Trial Details

Trial Dates

Other Details

  • Design prospective
  • Phase of Trial Phase I
  • Location Unknown
  • Focus Therapeutic Use

Interventions

Drugs Route Formulation
Sodium pyruvatePrimary Drug Inhalation
-

Trial History

Event Date Event Type Comment
24 Mar 2020 New trial record New trial record Updated 24 Mar 2020
17 Mar 2020 Other trial event According to an EmphyCorp media release, N115 Non-Steroidal Nasal Spray is currently being tested in clinical trials as a potential treatment for patients infected with the Coronavirus. Updated 24 Mar 2020

References

  1. Emphycorp. EmphyCorp News: Nitric Oxide is currently being tested in Clinical Trials as a Potential Treatment for Patients infected with the Coronavirus. Media-Rel 2020;.

    Media Release
Back to top